Resistance Oncology ApS: Financial statements 2020
CVR: 36945125
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -9,500 and a net result of DKK -7,652 compared with DKK 9,885 the year before. Equity in the 2020 report amounted to DKK -22,564.
- Gross Profit
- DKK -9,500
- Profit/Loss
- DKK -7,652
- Equity
- DKK -22,564
- Total Assets
- DKK 6,485
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -10 t. | -8 t. | -23 t. | - |
| 2019 | - | 14 t. | 10 t. | -15 t. | - |
| 2018 | - | -15 t. | -13 t. | -25 t. | - |
| 2017 | - | 51 t. | 1.1 mio. | -12 t. | 0 |
Official annual report
How creditworthy is Resistance Oncology ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Resistance Oncology ApS has published its annual report for 2019. Gross profit came to DKK 13,935, and the net result was DKK 9,885.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.